Brokers Issue Forecasts for CRBU Q1 Earnings

Key Points

• HC Wainwright forecasts a Q1 2027 loss of $0.11 per share for Caribou Biosciences, with projected losses narrowing to $0.05 per share by Q4. Its rating is Neutral, while the full-year consensus estimate is a loss of $0.88 per share.
• Analyst sentiment has weakened, including Leerink Partners’ price-target cut to $1 and Brookline Capital Markets’ downgrade to Hold. Overall, CRBU carries a consensus Hold rating with an average price target of $5.50.
• CRBU opened at $0.48, near its 1-year low of $0.45, after reporting a quarterly loss of $0.24 per share that beat estimates but revenue of $1.50 million below expectations; institutional investors own 77.51% of the stock.

Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) - HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for Caribou Biosciences in a research report issued to clients and investors on Thursday, October 8th. HC Wainwright analyst R. Burns expects that the company will post earnings per share of ($0.11) for the quarter. HC Wainwright has a "Neutral" rating on the stock. The consensus estimate for Caribou Biosciences' current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Caribou Biosciences' Q2 2027 earnings at ($0.08) EPS, Q3 2027 earnings at ($0.07) EPS and Q4 2027 earnings at ($0.05) EPS.

A number of other brokerages also recently issued reports on CRBU. Leerink Partners reissued a "market perform" rating and set a $1.00 price target (down from $4.00) on shares of Caribou Biosciences in a report on Wednesday. Wall Street Zen cut shares of Caribou Biosciences from a "hold" rating to a "sell" rating in a report on Saturday, September 19th. Bank of America decreased their price objective on shares of Caribou Biosciences from $6.00 to $5.00 and set a "buy" rating for the company in a research report on Friday, August 14th. Brookline Capital Markets downgraded shares of Caribou Biosciences from a "buy" rating to a "hold" rating in a research report on Wednesday. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Caribou Biosciences in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $5.50.

Caribou Biosciences Price Performance

NASDAQ:CRBU opened at $0.48 on Friday. The firm has a market cap of $51.59 million, a price-to-earnings ratio of -0.45 and a beta of 2.31. The company has a 50 day moving average price of $1.43 and a 200-day moving average price of $1.74. Caribou Biosciences has a 1-year low of $0.45 and a 1-year high of $3.54.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.32) by $0.08. The company had revenue of $1.50 million during the quarter, compared to the consensus estimate of $2.28 million. Caribou Biosciences had a negative return on equity of 89.11% and a negative net margin of 1,030.42%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in CRBU. CTC Alternative Strategies Ltd. purchased a new stake in Caribou Biosciences in the 1st quarter worth $29,000. Next Capital Management LLC purchased a new position in Caribou Biosciences during the second quarter valued at $35,000. Westmount Partners LLC acquired a new stake in shares of Caribou Biosciences in the first quarter valued at about $37,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Caribou Biosciences in the second quarter valued at about $41,000. Finally, Spark Investment Management LLC acquired a new stake in shares of Caribou Biosciences in the second quarter valued at about $42,000. Hedge funds and other institutional investors own 77.51% of the company's stock.

More Caribou Biosciences News

Here are the key news stories impacting Caribou Biosciences this week:

• Neutral Sentiment: Leerink Partners downgraded Caribou from “outperform” to “market perform” and set a $1 price target. Although the target implies substantial potential upside from recent levels, the rating change signals reduced confidence in the company’s near-term prospects. Leerink Partners Downgrades Caribou Biosciences to Market Perform
• Negative Sentiment: HC Wainwright & Co. cut its rating from “buy” to “neutral,” adding to the growing analyst caution surrounding Caribou’s pipeline and strategic direction. HC Wainwright Downgrades Caribou Biosciences
• Negative Sentiment: RBC downgraded Caribou from “outperform” to “sector perform” and slashed its price target to $1 from $10, retaining a speculative-risk designation. The steep target reduction reflects the expected impact of abandoning key development programs. RBC Downgrades Caribou Biosciences
• Negative Sentiment: Caribou said it would halt two CAR-T programs and cut its workforce, actions that raise questions about the company’s remaining pipeline and future operating strategy. Caribou to Halt CAR-T Programs and Cut Workforce
• Negative Sentiment: The company’s decision to explore strategic alternatives and discontinue CAR-T programs triggered a sharp selloff, while Brookline Capital Markets separately downgraded the shares from “buy” to “hold.” Caribou Shares Fall After Strategic Review
• Negative Sentiment: Coverage characterizing the company’s off-the-shelf cell-therapy effort as reaching the “end of the road” reinforces concerns that Caribou’s clinical strategy has materially narrowed. Caribou’s Cell-Therapy Strategy

About Caribou Biosciences

Caribou Biosciences, Inc is a clinical-stage biotechnology company developing genome-edited cell therapies for cancer and other serious diseases. The company uses its proprietary CRISPR-based chRDNA genome-editing platform to engineer immune cells, with an emphasis on allogeneic, or “off-the-shelf,” CAR-T therapies designed to target tumors without requiring cells to be collected from each individual patient.

Caribou's research and development programs have focused primarily on hematologic malignancies, including investigational CAR-T candidates directed at targets such as CD19 and BCMA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.